PEWAUKEE, Wis. - BiaCure Therapies, a non-invasive medical technology company, has announced it has been awarded a Small Business Innovation Research (SBIR) Phase II grant from the National Institutes of Health (NIH) in the amount of $2.6 million over three years to support the development of its proprietary high-frequency energy (HFE) therapy system for the treatment of onychomycosis, a fungal infection of the nail.
The funding will be used to further develop and validate BiaPulse, BiaCure's therapeutic device designed to deliver targeted HFE through a patient-friendly applicator. The system aims to achieve mycological cure through a short-course, non-invasive treatment, offering a potential breakthrough for patients who have failed or cannot tolerate traditional oral antifungal medications.
Laura King, CEO of BiaCure Therapies, said, "This SBIR grant is a strong validation of our science and approach. Onychomycosis affects over 35 million Americans, yet treatment options are limited, slow, and often ineffective. Our mission is to deliver a faster, safer, and more effective therapy that works beneath the surface of the nail—without systemic side effects."
The award will enable BiaCure to conduct clinical efficacy studies in collaboration with dermatology and podiatry experts, measuring fungal eradication. These clinical endpoints will help establish the efficacy of HFE as a mycological cure platform with potential applications beyond nail fungus.
